Mélanie Doré

Dr. Mélanie Doré


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TVTuan Le Van
Tuan Le Van
TGThomas Graillon
Thomas Graillon
JJJulian Jacob
Julian Jacob
EVELODIE VAULEON
ELODIE VAULEON
LFLoic Feuvret
Loic Feuvret
MPMatthieu Peyre
Matthieu Peyre

9 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AGAurore Goineau
Aurore Goineau
Loic CampionLoic Campion
Loic Campion
JCJean-Marie Commer
Jean-Marie Commer
BVBrigitte Vié
Brigitte Vié
AGAgnès Ghesquière
Agnès Ghesquière
Stéphane SupiotStéphane Supiot
Stéphane Supiot
Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT 02876237). The median age of the patients was 77 years (range 75–89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed.

3 February 2023 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
GDG. Delpon
G. Delpon
MRM. Renouf
M. Renouf
MLM. Langé
M. Langé
PBP. Blery
P. Blery
CDC. Dupas
C. Dupas
MDMélanie Doré
Mélanie Doré

10 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AMAnne-Victoire Michaud-Robert
Anne-Victoire Michaud-Robert
BSbenoit samain
benoit samain
LFLudovic Ferrer
Ludovic Ferrer
VFVincent Fleury
Vincent Fleury
MDMélanie Doré
Mélanie Doré
Stéphane SupiotStéphane Supiot
Stéphane Supiot
Prostate cancer (PCa) pelvic radiotherapy fields are defined by guidelines that do not consider individual variations in lymphatic drainage. We examined the feasibility of personalized sentinel lymph node (SLN)-based pelvic irradiation in PCa. Among a SLN study of 202 patients, we retrospectively selected 57 patients with a high risk of lymph node involvement. Each single SLN clinical target volume (CTV) was individually segmented and pelvic CTVs were contoured according to Radiation Therapy Oncology Group (RTOG) guidelines. We simulated a radiotherapy plan delivering 46 Gy and calculated the dose received by each SLN. Among a total of 332 abdominal SLNs, 305 pelvic SLNs (beyond the aortic bifurcation) were contoured (mean 5.4/patient). Based on standard guidelines, CTV missed 67 SLNs (22%), mostly at the common iliac level (40 SLNs). The mean distance between iliac vessels and the SLN was 11mm, and despite a 15mm margin around the iliac vessels, 9% of SLNs were not encompassed by the CTV. Moreover, 42 SLNs (63%) did not receive 95% of the prescribed dose. Despite a consensus on contouring guidelines, a significant proportion of SLNs were not included in the pelvic CTV and did not receive the prescribed dose. A tailored approach based on individual SLN detection would avoid underdosing pelvic lymph nodes that potentially contain tumor cells.

12 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LALoic Ah-Thiane
Loic Ah-Thiane
CRCaroline Rousseau
Caroline Rousseau
MAMaud Aumont
Maud Aumont
ACAxel CAILLETEAU
Axel CAILLETEAU
MDMélanie Doré
Mélanie Doré
Stéphane SupiotStéphane Supiot
Stéphane Supiot
The sentinel lymph node technique is minimally invasive and used routinely by surgeons, reducing the need for morbid extensive lymph node dissections, which is a significant advantage for cancer staging and treatment decisions. The sentinel lymph node could also help radiation oncologists to identify tumor drainage for each of their patients, leading to a more personalized radiotherapy, instead of a probabilistic irradiation based on delineation atlases. The aim is both to avoid recurrence in unexpected areas and to limit the volume of irradiated healthy tissues. The aim of our study is to evaluate the impact of sentinel lymph node mapping for radiation oncologists. This concept, relying on sentinel lymph node mapping for treatment planning, is known as lymph-flow-guided radiotherapy. We present an up-to-date narrative literature review showing the potential applications of the sentinel lymph node technique for radiotherapy, as well as the limits that need to be addressed before its routine usage.

17 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
YAYazan Abu-Shama
Yazan Abu-Shama
JSjulia salleron
julia salleron
FCFlorent Carsuzaa
Florent Carsuzaa
XSXu-Shan Sun
Xu-Shan Sun
CPCarole Pflumio
Carole Pflumio
Juliette THARIATJuliette THARIAT
Juliette THARIAT
Purpose: Management of head and neck cancers of unknown primary (HNCUP) combines neck dissection (ND) and radiotherapy, with or without chemotherapy. The prognostic value of ND has hardly been studied in HNCUP. Methods: A retrospective multicentric study assessed the impact of ND extent (adenectomy, selective ND, radical/radical-modified ND) on nodal relapse, progression-free survival (PFS) or survival, taking into account nodal stage. Results: 53 patients (16.5%) had no ND, 33 (10.2%) had lymphadenectomy, 116 (36.0%) underwent selective ND and 120 underwent radical/radical-modified ND (37.3%), 15 of which received radical ND (4.7%). With a 34-month median follow-up, the 3-year incidence of nodal relapse was 12.5% and progression-free survival (PFS) 69.1%. In multivariate analysis after adjusting for nodal stage, the risk of nodal relapse or progression was reduced with lymphadenectomy, selective or radical/modified ND, but survival rates were similar. Patients undergoing lymphadenectomy or ND had a better PFS and lowered nodal relapse incidence in the N1 + N2a group, but the improvement was not significant for the N2b or N2 + N3c patients. Severe toxicity rates exceeded 40% with radical ND. Conclusion: In HNCUP, ND improves PFS, regardless of nodal stage. The magnitude of the benefit of ND does not appear to depend on ND extent and decreases with a more advanced nodal stage.